Physician profile
Mortimer J Strong
NPI 1043292816
$1,164.41
in general payments reported to CMS, 2019-2025
16 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $29.44 · 2021: $23.31 · 2022: $17.48 · 2023: $118 · 2024: $426 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $369.57 | 2019-2025 | Veozah |
| Abbvie INC. | $225.46 | 2023-2025 | Viberzi, Linzess |
| Novo Nordisk INC | $128.15 | 2019-2024 | Rybelsus, Ozempic |
| Inspire Medical Systems, INC. | $85.69 | 2024-2025 | Inspire |
| Amgen INC. | $74.49 | 2019-2024 | Prolia, Evenity |
| Eisai INC. | $51.18 | 2023-2024 | |
| Lilly USA, LLC | $43.44 | 2019-2025 | Mounjaro |
| Pfizer INC. | $41.29 | 2019-2021 | |
| Gilead Sciences, INC. | $32.57 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $18.62 | 2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.24 | 2024 | |
| Medtronic, INC. | $17.48 | 2022 | |
| Amarin Pharma, INC. | $16.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.57 | 2024 | |
| Allergan, INC. | $14.89 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mortimer Strong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.